Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Observer-blind, Randomised, Placebo-controlled, Multi-country Study to Evaluate Reactogenicity, Safety, Immune Response, and Efficacy of an HSV-targeted Immunotherapy in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05298254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Observer-blind, Randomised, Placebo-controlled, Multi-country Study to Evaluate Reactogenicity, Safety, Immune Response, and Efficacy of an HSV-targeted Immunotherapy in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Completed
Start date
March 7, 2022
Completion date
June 12, 2025
Enrollment
505 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

herpes simplex